Press Releases

PRESS RELEASE For immediate release DEVONIAN HEATH GROUP INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES FOR MONTREAL AND EAST OF CANADA TODAY JUNE 3RD, 2021.   QUEBEC, June 3rd, 2021 – Devonian Health Group Inc. (“Devonian” or the...

PRESS RELEASE For immediate release DEVONIAN HEATH GROUP INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES IN BOSTON (USA) TODAY MAY 26, 2021.   QUEBEC, May 26, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a...

PRESS RELEASE For immediate release DEVONIAN HEATH GROUP INC. TO PRESENT AT THE CANADA INDIA HEALTHCARE SUMMIT 2021.   QUEBEC, May 13, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical...

PRESS RELEASE For immediate release DEVONIAN HEATH GROUP INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON THURSDAY, MAY 13, 2021.   QUEBEC, May 11, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical...

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP INC. RETAINS RENMARK FINANCIAL COMMUNICATIONS INC. TO PROVIDE INVESTOR RELATIONS SERVICES.   QUEBEC, April 14, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical...

PRESS RELEASE For immediate release Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering use of Thykamine™ for the treatment of Cardiovascular Diseases.   QUEBEC, March 30th , 2021 – Devonian Health Group Inc. (“Devonian” or...

PRESS RELEASE For immediate release Devonian Health Group provides more details on Previously Announced Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Population with Mild-to-Moderate Atopic Dermatitis and the Grant of Stock Options....

PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS.   QUEBEC, March 5, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...

PRESS RELEASE For immediate release Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Patients with Mild-to-Moderate Atopic Dermatitis.   Thykamine™ monotherapy achieved positive results by reaching the...

PRESS RELEASE For immediate release Devonian Health Group Announces voting results of the Annual General and Special Meeting.   QUEBEC,  – January 28, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...